Literature DB >> 16682275

Systemic mastocytosis.

Jamie Robyn1, Dean D Metcalfe.   

Abstract

Systemic mastocytosis is a fascinating disease with diverse clinical features. There have been numerous advances in understanding the basis of clinical manifestations of this disease and of its molecular pathogenesis in the last several decades. The development of methods to study mast cell biology using cell culture and murine models has proven invaluable in this regard. Clarification of the roles of mast cells in various biological processes has expanded our understanding of their importance in innate immunity, as well as allergy. New diagnostic methods have allowed the design of detailed criteria to assist in distinguishing reactive mast cell hyperplasia from systemic mastocytosis. Variants and subvariants of systemic mastocytosis have been defined to assist in determining prognosis and in management of the disease. Elucidation of the roles of the Kit receptor tyrosine kinase and signal transduction pathway activation has contributed to development of potential targeted therapeutic approaches that may prove useful in the future.

Entities:  

Mesh:

Year:  2006        PMID: 16682275     DOI: 10.1016/S0065-2776(05)89005-4

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  8 in total

1.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

3.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

4.  TLR signaling in mast cells: common and unique features.

Authors:  Hilary Sandig; Silvia Bulfone-Paus
Journal:  Front Immunol       Date:  2012-07-04       Impact factor: 7.561

5.  Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.

Authors:  Sofie Lieberoth; Simon Francis Thomsen
Journal:  Case Rep Med       Date:  2015-01-28

6.  Delayed diagnosis of adult indolent systemic mastocytosis.

Authors:  Carsten Sauer Mikkelsen; Andrew Nybo; Kristian Bakke Arvesen; Johan Holk-Poulsen
Journal:  Dermatol Reports       Date:  2014-02-17

Review 7.  IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.

Authors:  Arnau Navinés-Ferrer; Eva Serrano-Candelas; Gustavo-J Molina-Molina; Margarita Martín
Journal:  J Immunol Res       Date:  2016-12-21       Impact factor: 4.818

Review 8.  Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia.

Authors:  Michael P O'Connell; Jonathan J Lyons
Journal:  Curr Opin Allergy Clin Immunol       Date:  2020-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.